Skriver C, et al. - In this nationwide cohort study, researchers evaluated the correlation between postdiagnosis use of low-dose aspirin (75-150 mg), defined as ≥ 2 prescriptions filled within 1 year after prostate cancer diagnosis, and prostate cancer mortality. Study participants included men with incident prostate adenocarcinoma between 2000 and 2011. An overall effect of postdiagnosis low-dose aspirin use on prostate cancer mortality was not supported in this analysis. Results for extended exposure periods, however, suggested that low doses of aspirin may be inversely associated with mortality from prostate cancer after 5 years of cancer diagnosis.